4/A: Aadi Bioscience Executive Receives Stock Grant
Insider Transaction (Form 4/A)
David Dornan, Chief Scientific Officer of Aadi Bioscience, Inc., reported multiple transactions in common stock on September 15, 2026.
Summary
- Grant/award: acquired 85,887 Stock Option (right to buy) on September 15, 2026; holds 85,887 after (Direct).
- Grant/award: acquired 85,887 Restricted Stock Units on September 15, 2026; holds 85,887 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
David Dornan — Officer (Chief Scientific Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-15 | Grant/award | Stock Option (right to buy) | 85,887 | — | — | 85,887 |
| 2026-09-15 | Grant/award | Restricted Stock Units | 85,887 | — | — | 85,887 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-15 | Grant/award (85,887 shares) |
| 2026-09-15 | Grant/award (85,887 shares) |
Keywords
insider transaction, Form 4/A, WHWK, Whitehawk Therapeutics, Inc., neutral, David Dornan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.